Clinical Trial Update: LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

View source ↗

Summary

A clinical study is recruiting to evaluate local ablative therapy for oligoprogressive non-small cell lung cancer in patients receiving first-line osimertinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Status: RECRUITING